Buscar
Mostrando ítems 11-20 de 40
A theoretical analysis of the inhibition of the VEGFR-2 vascular endothelial growth factor and the anti-proliferative activity against the HepG2 hepatocellular carcinoma cell line by a series of 1-(4-((2-oxoindolin-3-ylidene)amino)phenyl)-3-arylureas
(Scholars Research Library, 2016)
An analysis of the relationships between electronic structure and the inhibition of the kinase activity of VEGFR-2 was carried out for a series of 1-(4-((2-oxoindolin-3-ylidene)amino)phenyl)-3-arylureas. A similar study ...
A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America
(Elsevier Masson SAS, 2018)
© 2018 Elsevier Masson SASBackground and aim: Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC) and liver transplantation (LT). Our study focused on changing trends of liver ...
Análisis del sistema de alistamiento y priorización para trasplante hepático de adultos en Chile
(Sociedad Médica de Santiago, Chile, 2020)
In Chile, organ allocation for liver transplantation (LT)
in adults is prioritized according to the MELD-Na score. Exceptions such as
Hepatocellular Carcinoma (HCC) and other non-HCC exceptions receive a
score called ...
Carcinoma hepatocelular. Tratamiento multimodal
(Asociaciones Colombianas de Gastroenterología, Endoscopia digestiva, Coloproctología y HepatologíaColombia, 2008-02-14)
El carcinoma hepatocelular ha aumentado su incidencia en
el hemisferio occidental. Existen varias modalidades de tratamiento. En este artículo revisaremos las opciones actualmente
disponibles.
Results of liver transplantation for hepatocellular carcinoma in a multicenter latin American cohort study
(Mexican Assoc Hepatology, 2018)
Background and aims. Background and aims. He Background and aims. terogeneous data has been reported regarding liver transplantation (LT) for hepatocellular carcinoma
(HCC) in Latin America. We aimed to describe treatment ...
Direct-acting antivirals and Hepatocellular Carcinoma: No evidence of higher wait-list progression or posttransplant recurrence
(Wiley, 2020)
The association between direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC) wait-list progression or its recurrence following liver transplantation (LT) remains uncertain. We evaluated the impact of DAAs on ...